NEWDAY-ABC

Summary

Many people recovering from early-stage breast cancer are above a healthy weight. This can increase the risk of cancer returning and negatively impact long-term health. Eating well, staying active and managing weight may improve recovery and wellbeing. Despite this, there is a lack of lifestyle support offered after treatment.

A programme of support has been developed (the NEWDAY-ABC programme) to help patients recovering from early stage HER2 negative (HER2-ve) breast cancer to achieve a healthy weight and increase their physical activity.

During a small scale study, the programme was found to be acceptable to those involved and potentially helped people to lose weight and reduce their BMI and waist and hip circumference.

We are now conducting a larger study in the North of England that will explore if the NEWDAY-ABC programme can help people recovering from early-stage breast cancer treatment to develop the skills and confidence needed to make healthy lifestyle changes.

What we plan to do

The NEWDAY-ABC trial is a Phase 3, multi-centre, two-arm randomised controlled hybrid intervention-implementation study sponsored by the University of Hull (IRAS ID: 362285).  This trial will evaluate a lifestyle intervention in adults with HER2-negative stage II–III early breast cancer. The trial will recruit 375 participants from NHS sites across Yorkshire, Greater Manchester and Cheshire.

The trial aims to demonstrate the effectiveness and cost-effectiveness of the NEWDAY-ABC and facilitate its implementation into the care pathway.

There will be a 9-month internal pilot to assess assumptions on recruitment, retention and fidelity of the intervention